Survey
Quarterly Survey: Alzheimer's Disease and BIIB's Leqembi July 2024
Ticker(s): BIIB, LLYThe survey includes 20 neurological disease specialists.
How many patients with early Alzheimer's disease (mild cognitive impairment or mild dementia stage of disease) do you manage?
Do you currently prescribe Leqembi (lecanemab)?
What % of your Alzheimer's patients are you prescribing Leqembi (lecanemab)?
Describe the type(s) of Alzheimer's patients that you consider/qualify for Leqembi (lecanemab) therapy. Please be specific.
How many of your Alzehimers patients have you started on Leqembi (lecanemab) in the past 30 days?
How many of your Alzehimers patients do you expect to start on Leqembi (lecanemab) in the next 30 days?
Are you more willing to prescribe Leqembi (lecanemab) now than you were 90 days ago? Why or why not? Please be specific.
What factors are helping/hindering your willingness to prescribe Leqembi (lecanemab)? Please be specific.
What criteria needs to be demonstrated to payors for coverage of Leqembi (lecanemab)?Please be specific.
How satisfied are you with the level of support you're receiving from Biogen/Eisai?
- Very Satisfied
- Satisfied
- Somewhat satisfied
- Neither satisfied nor dissatisfied
- Somewhat dissatisfied
- Dissatisfied
- Very dissatisfied
- Other
Has the level of support from Biogen/Eisai gotten any better or worse in the past 90 days?
- Support is better
- Support is the same
- Support is worse
Do you expect your Leqembi prescriptions to increase over the next 12 months?
- Yes
- No
By what % do you expect Leqembi (lecanemab) prescriptions to increase in the next 12 months and why?
The FDA recently granted approval of the subcutaneous form of Leqembi. How will the approval affect your Leqembi prescriptions?
Why is that? Please elaborate on your response above.
Given the recent FDA approval of LLY's Kisunla (donanemab), what do you expect the % split between Kisunla (donanemab) and Leqembi (lecanemab) to be?
- Kisunla (donanemab):
- Leqembi (lecanemab):
Why is that? Please elaborate on your response above.
How would you describe the overall insurance coverage for Alzheimer's?
Do you think the recent FDA approval of LLY's Kisunla (donanemab) impacts insurance coverage in any way? Please explain.
What is your projected outlook for the prescribing of anti-amyloid medications over the next five years within your practice or institution?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Leqembi?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Kisunla (donanemab)?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
